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Background: This study investigated whether long-term treatment with antiepileptic drugs (AEDs) had negative
effects on statural growth and serum calcium levels in children with epilepsy in Taiwan.
Methods: Children with epilepsy treated with one prescription of AEDs (monotherapy) for at least 1 year were
selected. The AEDs included valproic acid (VPA; Deparkin) in 27 children (11 boys and 16 girls) aged 4-18 years,
oxcarbazepine (Trileptal) in 30 children (15 boys and 15 girls) aged 5-18 years, topiramate (Topamax) in 19 children
(10 boys and 9 girls) aged 6-18 years, and lamotrigine (Lamicta) in eight children (5 boys and 3 girls) aged
5-13 years. Patients with a history of febrile convulsions were selected as the controls.
Results: One year of VPA treatment significantly impaired the statural growth of pediatric patients with epilepsy
(p < 0.005) compared with the control group. The underlying mechanism may have been due to the direct effect of
VPA on the proliferation of growth plate chondrocytes rather than alterations of serum calcium.
Conclusions: These results raise serious concerns about the growth of pediatric epilepsy patients who use AEDs,
and potentially the need to closely monitor growth in children with epilepsy and adolescents under AED
treatment, especially VPA.
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The skeletal system determines a person’s height. Al-
though stiff and unyielding, bone is a living tissue that
continuously remodels throughout life. Specialized cells
are engaged in the bone remodeling and turnover pro-
cesses, such as osteoblasts initiating bone formation,
osteocytes monitoring bone mechanical stresses, and
osteoclasts absorbing bone [1]. The growth plate is at
the end of long bones, is made up of chondrocytes at
different stages of differentiation, and is divided histo-
logically into three distinct zones: resting, proliferative,
and hypertrophic [2]. Longitudinal bone growth is pri-
marily achieved through the action of chondrocytes in
the proliferative and proliferative zones of the growth
plate [3]. Apart from the effects of circulating systemic
and local hormones, calcium and other chemicals, which
are mainly provided by bone to maintain the intra-and
extracellular mineral pools, can work in cohort with* Correspondence: fanhuengchuen@yahoo.com.tw
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reproduction in any medium, provided the orosteoblasts, osteocytes, and extracellular matrix proteins
to mineralize osteoid [4]. Calcium is crucial for normal
epiphyseal growth plate development, and changes in
extracellular calcium modulate the function of chondro-
cytes [5]. Proliferation of epiphyseal growth plates results
from a complex interplay among a net effect of hormones
and growth factors, which may directly or indirectly affect
the serum levels of calcium and the condition of those
cells, leading to final stature.
Epilepsy is a chronic condition characterized by recur-
rent clinical events or epileptic seizures, which occur in
the absence of a metabolic or toxic disease or fever [6]. In
addition, the diagnosis of epilepsy can possibly be made
after only one epileptic seizure if an “endearing predispos-
ition of the brain to future seizures” exists. The World
Health Organization (2001) estimates a prevalence of 0.8%
in the general population, and the prevalence in Taiwan
has been reported to be 0.28% [7]. Epilepsy often requires
long-term antiepileptic drug (AED) therapy. However,
prolonged AED administration is associated with a num-
ber of problems such as behavioral and psychiatric. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cratic reactions, and drug interaction effects [8]. Although
some studies suggest that patients with epilepsy treated
with AEDs have an increased risk of fractures, low bone
mineral density (BMD), and abnormalities in bone meta-
bolism, skeletal diseases associated with long-term AED
treatment are seriously unrecognized [9,10]. In a survey
of >1000 adult and pediatric neurologists designed to
assess the awareness of the effects of AED therapy on
bone health, only 28% of adult and 41% of pediatric
neurologists reported screening their patients for bone
diseases [11]. A lack of consensus between physicians con-
cerning the impact of AED therapy on bone may put epi-
lepsy patients at risk, especially children, with regard to
bone health or developing bone diseases.
Evidence suggests that patients with epilepsy are predis-
posed to bone problems and fractures [12]. However, one
meta-analysis concluded that the deficit in bone mineral
density was too small to explain the increase in the risk of
fractures in patients with epilepsy [13]. Bone abnormalities
such as short stature, abnormal dentition, rickets, and
osteomalacia have been reported to be linked to the use of
AEDs [12,14,15]. The mechanisms through which AEDs
cause abnormal bone metabolism and increase fractures
are not fully understood. Reports have shown that hypo-
calcemia is an important biochemical abnormality in pa-
tients receiving cytochrome P450 enzyme-inducing AEDs,
which potentially increase the catabolism of vitamin D to
inactive metabolites, leading to reduction of calcium
[9,10,16]. However, some non-enzyme-reducing AEDs
have also been linked with low bone mass [10,17,18]. A
new generation of AEDs, including oxcarbazepine (OXA),
topiramate (TPM), and lamotrigine (LTG), have been
approved as therapeutic options for epilepsy. However, to
date, there is no consensus about the effect on bone
metabolism in individuals receiving these AEDs, and no
definitive guidelines for evaluation or treatment have yet
been determined. Most epileptic patients are diagnosed
and treated in childhood and adolescence, and this period
is crucial in attaining peak bone mass. Therefore, it is
worth investigating whether AEDs affect bone growth in
pediatric patients with epilepsy.
The maintenance of growth and bone health is a com-
plex process that can be influenced by the underlying
diseases and nutritional status of a patient, but also by
chemical factors. If AED treatment is associated with
disturbance of statural growth and calcium metabolism,
clinical parameters such as serum calcium levels and sta-
tural growth may reveal abnormalities after AED therapy
in pediatric patients with epilepsy. The aim of this study
was to evaluate the effects of AED monotherapy inclu-
ding VPA, OXA, TPM, and LTG on alterations in serum
calcium levels and statural growth in drug-naïve, Taiwanese
pediatric patients newly diagnosed with epilepsy. To gainfurther insight into the mechanism of action of AEDs on
linear bone growth, we examined the effects of AEDs on
cultured growth plate chondrocytes in vitro on cell proli-
feration using a tetrazolium methylthiotetrazole (MTT)
assay. Our results showed that, instead of affecting serum
calcium levels, VPA may interfere with the proliferation of
growth plate chondrocytes in a direct manner and signifi-
cantly affect the statural growth of children with epilepsy.
These results raise serious concerns about the growth of
pediatric epilepsy patients who use AEDs, and potentially
the need to closely monitor growth in epileptic children
and adolescents under AED treatment, especially VPA.
Methods
Study subjects
From February 2009 to January 2011, children with newly
diagnosed seizures, which were classified according to the
report of the International League Against Epilepsy (ILAE)
Commission on Classification and Terminology 2005 [19],
including generalized, tonic-clonic (ICD-9-CM diagnosis
code 345.10), absence (ICD-9-CM diagnosis code 345.0),
myoclonic (ICD-9-CM diagnosis code 345.1), clonic (ICD-
9-CM diagnosis code 345.1), tonic (ICD-9-CM diagnosis
code 345.1), atonic (ICD-9-CM diagnosis code 345.1), and
focal (ICD-9-CM diagnosis code 345.5) seizures. The chil-
dren were attending the pediatric outpatient department,
emergency department, or were admitted to the pediatric
ward and started on standard recommended doses of val-
proic acid (VPA; Deparkine solution; Sanofi Winthrop
Industrie, Paris, France; starting dose 20 mg/kg/day, main-
tenance dose 20-40 mg/kg); OXA (Trileptal suspension
form; Novartis, Rueil-Malmaison, France; starting dose
5-10 mg/kg/day, maintenance dose 20-40 mg/kg); TPM
(Topamax 100 mg tablets, Janssen-Cilag, Baar, Switzerland;
starting dose 0.5-1 mg/kg/day, maintenance dose 3-9
mg/kg); or LTG (Lamictal 50 mg tablets, GlaxoSmithKline,
Zeist, Netherlands; starting dose 0.5 mg/kg/day, main-
tenance dose 5-15 mg/kg) for at least 1 year. All children
were ambulatory and without any dietary restrictions. The
serum levels of patients taking VPA were routinely moni-
tored, and the levels were within the therapeutic range
(50-100 μg/mL). Patients were excluded if they had: (1) a
history of taking AEDs or other medications that affect
bone metabolism (e.g., steroids, diuretics, vitamin D,
calcium supplements, bisphosphonates, or calcitonin);
(2) any endocrine or medical disorders (e.g., hypothy-
roidism or renal diseases); (3) a history of nutritional defi-
ciency; (4) limitations in ambulation or daily physical
activity; (5) any progressive neurological disorders other
than epilepsy; and (6) clinical/biochemical evidence of
rickets or growth retardation. All of the children resided
in Taipei, were ambulatory, had normal age-appropriate
activity, and nutritionally adequate diets. Subjects with a
history of simple febrile convulsions (ICD-9-CM diagnosis
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height, weight, and body mass index (BMI) were recorded.
All patients were followed up every 3-6 months at the
pediatric outpatient department.
Estimation of serum calcium
Five-milliliter venous blood samples were collected from
all patients for the measurement of serum total and
ionized calcium levels. Cobas c501 (Roche Diagnostics,
Mannheim, Germany) and NOVA CCX (NovaBiomedical,
Waltman, MA, USA) were used for the measurement of
serum total and ionized calcium levels, respectively.
Consent and ethical approval
The current study was approved by the scientific and
ethics committees of Tri-Service General Hospital
and National Defense Medical Centre, Taipei, Taiwan
(TSGHIRB approval number 100-05-239). All parents,
guardians, or legal representatives signed an informed
consent form before participation in the study.
Reagents
Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture
F-12 HAM Medium (DMEM/F-12) were purchased from
Gibco Life Technologies (Carlsbad, CA, USA). Dimethyl-
sulfoxide (DMSO), fetal bovine serum (FBS), and MTT
were purchased from Sigma (St. Louis, MO, USA). All
other reagents were purchased from Sigma and were tis-
sue culture grade. The drugs were obtained as described
above. In the in vitro study, the choice of AED concentra-
tion was based on therapeutic plasma concentrations of
the respective drug in the patients. The following concen-
trations were used: VPA, 415 μM (60 μg/mL); OXA,
30 μM (7 μg/mL); TPM, 30 μM (10 μg/mL); LTG, 20 μM
(5 μg/mL) [20].
Cell isolation
Chondrocytes were isolated and cultured as described
previously [21]. Male 3-week-old Sprague–Dawley rats
(50-60 g each) were obtained from BioLASCO Taiwan
(Taipei, Taiwan). All experiments were approved by the
local institutional animal care and use committee, Tri-
Service General Hospital and National Defense Medical
centre, Taipei, Taiwan, ROC (IACUC-12-233). The epi-
physeal growth plate of the tibia was separated by clea-
ning the cartilage plate of muscular tissue, periosteum,
and perichondrium. The proximal epiphysis was divided
by a transverse cut with a sharp scalpel, and the cartilage
plate was separated distally from the calcification zone
of the tibial metaphysis. Isolated growth plates were
digested with 3 mg/mL collagenase type H (Sigma) for
3 h at 37°CC. After thorough washing, cells were
counted using a Neubauer chamber. Cell viability, exa-
mined by trypan blue exclusion, was >95%.Monolayer cultures
Cell monolayers were cultured in DMEM/F-12 medium
supplemented with 10% FBS, 100 IU/mL penicillin
(Gibco), and 100 mg/mL streptomycin (Gibco). The cells
were grown in 75-cm2 plastic culture flasks (Corning,
Corning, New York, NY, USA) and incubated at 37°CC
until confluence. They were then washed three times
with phosphate-buffered saline (PBS), harvested using
trypsin-EDTA (Gibco), and subcultured at a 1:3 ratio.
Chondrocytes were immunopositive for anti-S100 pro-
tein (data not shown). Growth-plate chondrocytes grown
to passages 3 and 5 were then plated at 1 × 104 cells/mL
into 96-well plates for the MTT assay. The medium with
the AEDs was changed daily and cells were collected for
assay on Day 5. All cells were maintained in an atmos-
phere of 5% CO2 and 95% air at 37°CC.
Evaluation of rat chondrocyte proliferation by a MTT
assay
Cell viability was determined by measuring the activity
of cellular dehydrogenase that could cleave MTT (3-
(4,5-dimethylthiazol-2-il)-2,5-diphenyl tetrazolium bromide)
(Sigma) in a colorimetric assay as described previously [22].
Activate dehydrogenase reduced MTT in viable cells to
form insoluble formazan, which was then dissolved in
DMSO and quantified spectrophotometrically at 540 nm.
Growth-plate chondrocytes (1 × 104 cells/mL) were seeded
into 96-well plates (Corning) in triplicate and kept under
5% CO2 at 37°CC. After 24 h incubation, the cell culture
medium was replaced daily by one containing fresh com-
plete medium or fresh complete medium with 0.1% DMSO
as a vehicle, or fresh complete medium with an AED for
5 days. Two hundred microliters of MTT (0.5 mg/mL) was
then added to each well and the mixture was left to incu-
bate for 3 h at 37°CC. The reaction was then stopped by
injecting 200 μL DMSO per well. The plates were shaken
for 5 min, and then the optical density at 540 nm was
determined on a microplate reader (μQuant, BIO-TEK
Instruments Inc., Winooski, VT, USA) with KC Junior ana-
lysis software, version 1.5 (BIO-TEK Instruments). At least
three such experiments were performed for each treatment.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware, version 13.0 (Chicago, IL, USA). Age, sex, weight,
BMI, AED, and levels of calcium were expressed as the
mean ± standard deviation (SD). Comparisons of the
data were conducted by one-way analysis of variance
(ANOVA). The Student’s paired t test was used to com-
pare serial changes in serum calcium after 1-year treat-
ment with AEDs and the control group. Comparisons of
the data from cell proliferation studies were carried out
by ANOVA. A p value <0.05 was considered statistically
significant; *represents p < 0.05 and **p < 0.005.
Table 1 Clinical parameters of children with epilepsy
VPA OXA TPM LTG Control p value
Subject number 27 30 19 8 30
Age (mean ± SD) 9.59 ± 3.90 10.43 ± 3.73 9.74 ± 3.28 7.50 ± 3.30 9.10 ± 4.22 0.36
Gender (% Female) 59% 50% 47% 38% 40% 0.64
Height (cm mean ± SD) 129.76 ± 20.00 137.83 ± 20.49 133.79 ± 16.83 123.63 ± 16.95 133.77 ± 23.24 0.4
Weight (kg mean ± SD) 32.26 ± 17.47 37.06 ± 16.29 32.42 ± 14.25 26.81 ± 10.43 33.45 ± 16.60 0.54
BMI (mean ± SD) 18.05 ± 4.19 18.65 ± 3.94 17.28 ± 3.42 17.00 ± 3.09 17.59 ± 4.07 0.69
Age, sex, weight, height, and BMI in epilepsy patients before AED treatment and in the control group.
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Clinical characteristics
The demographic characteristics of the patients are shown
in Table 1. There were no significant differences between
the control and study patients in age, sex, height, weight,
or BMI.
Changes in statural growth
A statistically significantly lower body height was found
in patients treated with VPA compared with the controls
(p < 0.005; Figure 1). However, there were no significant
differences between the control group and patients
treated with OXA, TPM, or LTG.
Serum total and ionized calcium levels
Levels of serum total and ionized calcium did not differ
significantly among the patients treated with VPA, OXA,
TPM, and LTG compared with the controls (p > 0.05;
Figure 2). None of the drugs affected the level of serum
calcium in the epilepsy patients.
Evaluation of growth-plate chondrocyte proliferation
The influence of the vehicle (0.1% DMSO) and AEDs, in-
cluding VPA, OXA, LTG, or TPM on growth-plate chon-
drocyte proliferation was expressed as a percentage of cell
growth in six independent experiments. In comparison(cm)
**
Figure 1 VPA significantly affected growth of children with epilepsy.
children with epilepsy treated for 1 year with AEDs, including VPA, OXA, TP
standard errors. Significant differences (**, p < 0.005) were found between twith the controls, the cell proliferation rate was signifi-
cantly decreased to 84.45 ± 2.3% when the cells were ex-
posed to VPA. However, there were no significant effects
on the proliferation of the chondrocytes with OXA, LTG,
or TPM (Figure 3).
Discussion
In the current study, there were significant reductions in
statural growth in the epilepsy patients who were treated
with VPA for 1 year compared with the control group.
However, there were no significant differences in statural
growth in those who were treated with OXA, LTG, or
TPM. In support of our findings, Sheth et al. [23] and
Kafali et al. [24] reported decreased bone mass in the
lumbar spine and middle of the distal radius in children
without physical handicaps who were treated with VPA
for ≥6 [23] or 18 [24] months. This suggests that VPA
can disturb bone growth. Childhood and adolescence are
crucial periods in which to attain peak bone mass, and
most patients with epilepsy are diagnosed and treated in
this period, therefore, AEDs, and especially VPA, should
be used with caution in pediatric patients with epilepsy.
Calcium is crucial for normal epiphyseal growth plate
development. However, hypocalcemia is reported to affect
3–30% of patients with epilepsy treated with AEDs [25],
and this has been postulated to explain AED-associatedComparison of changes in body height among the control group and
M, and LTG. The bars represent means, and the whiskers represent




After 1 year follow up
Seizure onset
After 1 year follow up
A
mg/dL
Figure 2 AEDs did not affect the level of calcium in children
with epilepsy. Comparison in the changes of serum total (A) and
ionized (B) calcium concentration among the control group and
children with epilepsy treated for 1 year with AED, including VPA,
OXA, TPM, and LTG. The bars represent means, and the whiskers
represent standard errors.
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P450 enzymes may cause reduced levels of bioavailable
vitamin D, leading to decreased absorption of calcium in
the gut, resulting in hypocalcemia and an increase in cir-
culating parathyroid hormone, which then increases the
mobilization of bone calcium stores and subsequent bone
turnover [9,10,26]. In the current study, no significant
changes in serum total and ionized calcium concentra-
tions were found in the patients after 1 year treatment
with VPA, OXA, LTG, or TPM. In addition, vitamin D
deficiency has been reported to not affect low BMD in
epilepsy patients after correcting for age and duration on































Figure 3 VPA significantly reduced the proliferation of rat
growth-plate chondrocytes. The influence of vehicle (0.1% DMSO)
and AEDs, including VPA, OXA, LEV, LTG, and TPM on chondrocytes
of rat growth-plate proliferation in MEM:HAM-F12 (1 : 1) medium
with 10% FBS, expressed as cell growth percentages. The mean
values are presented on top of the bars with the standard error
value. (**, p < 0.005).notion that AEDs can cause bone loss without inducing
hypocalcemia and vitamin D deficiency, suggesting that
other mechanisms may be responsible.
VPA, a cytochrome P450 enzyme inhibitor, is widely
used for the management of epilepsy [30]. In the current
study, the statural growth of pediatric patients was signifi-
cantly affected by the use of VPA compared with the con-
trol subjects, and this was not through alterations in the
concentration of calcium. The reported effects of VPA on
bone loss in patients with epilepsy are diverse, including
accelerated or no bone loss [30-33], hyper- and hypocalce-
mia [33,34], or normal serum calcium level [35,36]. To
clarify these contradictions, we examined the effects of
AEDs on the proliferation of cultured growth plate chon-
drocytes in vitro, and showed that cell proliferation was
significantly inhibited by VPA, which is similar to our
clinical findings. However, also in agreement with our
clinical findings, no distinct effects on the inhibition of
proliferation in the growth-plate chondrocytes were seen
in the patients who were treated with OXA, TPM, or
LTG.
OXA, TPM, and LTG are approved for monotherapy or
adjunctive therapy in patients with partial and generalized
seizures. Despite being safer and having better tolerability,
data regarding these new generation AEDs on bone health
in children are controversial. OXA and TPM are cyto-
chrome P450 isoenzyme inducers. Epilepsy patients trea-
ted with OXA are reported to have an increased risk
of fractures [37], lower BMD [28], and decreased
25-hydroxyvitamin D3 levels [38]. TPM is associated with
renal calculi, osteomalacia and/or osteoporosis [39], and
mild hypocalcemia and increased bone turnover [40]. LTG
does not induce or inhibit cytochrome P450 isoenzymes
[41]. Children treated with LTG and/or VPA for >2 years
have shorter stature, lower BMD, and reduced bone for-
mation compared with controls [15]. However, because of
combined therapy, the seizure status in those children
may be more severe and their physical activity lower. A
lower physical activity may cause more severe bone abnor-
malities than AEDs do. In fact, all available data indicate
that LTG monotherapy does not alter BMD, calcium, or
vitamin D levels [16,42,43]. Although we did not find dis-
turbances in serum calcium and statural growth in the
epilepsy patients who were treated with OXA, TPM, or
LTG, our findings do not contradict previous reports. This
is because OXA, TPM, and LTG may alter bone micro-
structure and bone turnover rate but maintain an ad-
equate bone mass, leading to a normal statural growth
rate in vivo and a normal proliferation of bone cells
in vitro. Ultimately, all of these factors may have an impact
on longitudinal skeletal growth and risk of fractures.
It was unclear how VPA directly interfered with the
proliferation of growth-plate chondrocytes in the current
study. VPA at a therapeutic dose is an effective inhibitor
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tone tails and chromatin relaxation owing to disruption
of histone–DNA and histone–histone interactions [44].
Apoptosis of chondrocytes is the main process for
growth-plate remodeling, therefore, it is worth investi-
gating whether VPA delays cell-cycle progression [45],
modulates caspases and/or induces apoptosis [46], thereby
causing inhibition of cell growth and proliferation, leading
to short stature.
The current study had a number of limitations. First,
the sample size was small and the duration of follow-up
was only 1 year. It is possible that statistically significant
lower statures would have been discovered after 1 year
in children taking some or all of these AEDs if larger
sample sizes and longer duration had been used. Second,
the literature shows that enzyme-inducing AEDs in-
crease the catabolism of vitamin D to inactive metabo-
lites, potentially explaining why some enzyme-inducing
AEDs are associated with increased risk of osteoporosis
[9,14,15]. However, it has been reported that vitamin D
deficiency may not affect BMD in epilepsy patients after
correcting for age and duration on AEDs [27]. If the
level of vitamin D is affected by AED, the downstream
of the calcium level should be cascaded. The lack of
vitamin D was a limitation of our study for a more com-
prehensive understanding of AED on growth. Third, rat
chondrocytes in the growth plate cannot truly represent
in vivo human conditions. Finally, this study was not
randomized. These limitations may have led to some
bias in analyzing the effects of AED on the growth of
children with epilepsy.
The use of these AEDs for children and adolescents
with epilepsy is growing, and the number of reported
side effects of the newer AEDs is increasing. Therefore,
our findings are valuable, because we performed a longi-
tudinal study on AED monotherapy that indicated the
risks of short stature in pediatric patients receiving
AEDs. Early identification and proper management of
AED-related growth retardation and associated bone
health require greater public awareness and understand-
ing of these adverse effects in children and adolescents.
Conclusions
AEDs are effective and necessary for children with epi-
lepsy. However, long-term AED therapy, and especially
VPA, may predispose patients to growth and bone health
abnormalities. Childhood and adolescence are crucial
growth periods, thus, prevention of growth retardation
and adverse bone health with the use of VPA may be ad-
dressed by judicious use of AEDs coupled with improved
nutrition and promotion of weight-bearing activities.
Moreover, the new generation of AEDs such as OXA,
LTG, and TPM may be alternative choices because of
fewer adverse effects.Competing interests
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